At the forefront of therapies for rare and orphan diseasesTM
HOME CONTACT US         
Share
about us| programs| science & technology | patient advocacy | clinical studies | investors | collaborations | news & events
 
Amicus Therapeutics is a biopharmaceutical company developing next-generation treatments for a broad range of human genetic diseases, with a focus on improving therapies for lysosomal storage diseases.
More...
NEWS
11/18/2014 Amicus Therapeutics Prices Underwritten Offering of Common Stock
11/17/2014 Amicus Therapeutics Announces Public Offering of Common Stock
11/15/2014 Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac and Composite Endpoints from Fabry Monotherapy Study 012 at American Society of Nephrology
More...

U.S. NEWS
Agonizing Choices for Lives Saved by Miracle Drugs
By GEETA ANAND

Seven months ago, Megan Crowley made a gutsy decision: to undergo a radical surgery to  straighten out her spine, which has been crippled by Pompe disease. Photo: Lexey Swall
Click Here to Read the Article
Click Here to View the Video

Copyright © 2014 Amicus Therapeutics, Inc. All rights reserved.   Terms of Use | Privacy Policy